Clinical trial
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
NCT00418236 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00418236 |
|---|---|
| Title | Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density |
| Official title | Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Breast Cancer |
| Enrollment | 400 |
| Start date | Oct 1, 2006 |
| Completion | Apr 1, 2010 |
| First posted | Jan 4, 2007 |
| Last update posted | Aug 19, 2010 |
| Countries | Argentina, Brazil, Bulgaria, Canada, Chile, Croatia, Denmark, Estonia, Mexico, Netherlands, Poland, Romania and 2 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: